Navigation Links
Adherence course reduces hypertension
Date:2/16/2011

A high proportion of patients with high blood pressure are failing to take their medication properly and would benefit clinically from a course of 'adherence therapy', according to new research from the University of East Anglia (UEA).

High blood pressure or hypertension is one of the major cardiovascular diseases worldwide. It leads to stroke and heart disease and costs more than $300 billion each year. Around a quarter of the adult population is affected including 10 million people in the UK.

Around half of patients with hypertension fail to reduce their blood pressure because they are not taking their prescribed medication correctly. Some cease taking their medication altogether, others only take some of it, and others do not follow the instructions to take their medicine after food, for example.

The reasons for this non-adherence are complex and include ambivalence about taking drugs, concerns over side effects, and complexity of treatement regimes. Previous attempts to improve adherence with information leaflets, monthly outpatient visits, reminders and self-monitoring have been shown to be mostly ineffective.

The UEA resesarchers studied 136 patients with high blood pressure in three outpatient clinics in Jordan. Half were given a course of seven weekly 'adherence therapy' sessions and half continued with their usual treatment. The 20-minute face-to-face sessions allowed a trained clinician to provide tailored information about the illness and treatment, and explore the patient's individual beliefs, fears and lifestyle.

Published today in the Journal of Human Hypertension, the results show that the patients given adherence therapy took 97 per cent of their medications (compared with only 71 per cent for those given treatment as usual) and, on average, reduced their blood pressure by around 14 per cent taking it to just above the healthy range.

Lead author Prof Richard Gray of UEA's School of Nursing and Midwifery said: "Our findings suggest a clear clinical benefit in these patient-centred sessions.

"High blood pressure affects millions of people in both the developed and developing world and the problem is likely to increase dramatically over the next 15 years. Tackling the widespread failure to take medication correctly would lead to a major reduction in stroke and heart disease.

"If adherence therapy were a new drug it would be hailed as a potentially major advance in hypertension treatment."

Adherence therapy was originally developed by Prof Gray for patients with mental health problems who failed to take their medication correctly. The total cost of delivering a course of seven weekly sessions is calucated to be approximately 80 per person. Although the UEA study was not designed to formally evaulate cost effectiveness, other studies predict that a long-term reduction of blood pressure would lead to a reduction in stroke of 56 per cent and a reduction in chronic heart disease of 37 per cent suggesting that adherence therapy would likely be a cost-effective intervention.


'/>"/>

Contact: Simon Dunford
s.dunford@uea.ac.uk
44-160-359-2203
University of East Anglia
Source:Eurekalert

Related medicine news :

1. Side effects of hormonal breast cancer therapy increased; may affect treatment adherence
2. Medication adherence improves blood pressure control in chronic kidney disease
3. Adherence to practice guidelines may reduce bleeding in cirrhosis patients
4. Electronic Monitoring of Asthma Med Use May Boost Adherence
5. NACDS RxIMPACT "Hill Day" Features More Advocates Increased Focus on Medication Adherence
6. Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines
7. NHGRI charts course for the next phase of genomics research
8. CTO summit and left main coronary interventions course will feature latest research and techniques
9. CTO Summit & Left Main Coronary Interventions Course to be held Feb. 14-16, 2011, in NYC
10. Strong scientific findings presented at AIDS 2010 point to promise ahead and underscore the need to stay the course
11. Atlanta School of Sleep Medicine Offers Physician Board Review Course in October 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: